Roche may have hit a snag in its bid to push a Tecentriq-Cotellic combo into colorectal cancer. The company temporarily stopped enrolling patients in a clinical trial after reports that four patients treated with the duo had died. More: Roche
read morePfizer has been looking to expand kidney cancer drug Inlyta’s use to renal cell carcinoma patients at a high risk of disease recurrence following surgery—but on that front, it’s fallen short. More: Pfizer strikes out on Inlyta expansion bid with postsurgery kidney cancer failure Source:
read moreA month after doling out its first grant ever—to help Themis develop vaccines against Lassa fever and MERS—the Coalition for Epidemic Preparedness Innovations has promised to fund Inovio’s efforts in the same diseases. More: On the heels of Themis deal,
read moreJust three days after celebrating another FDA approval for its ovarian cancer drug Rubraca, Clovis Oncology disclosed trouble with the feds. The SEC is zeroing in on Clovis’ once-promising therapy rociletinib, which went down in flames in 2015—and whether the
read moreSpurred by U.S. tax breaks, Amgen will build a $165 million next-generation biologics plant in West Greenwich, Rhode Island. More: Amgen names Rhode Island as location for its new U.S. next-gen biologics plant Source: fierce
read moreNovartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex (TSC)-associated partial-onset seizures. More: Novartis’ Afinitor Disperz wins new TSC-related approval Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals